Search Results

There are 2343 results for: content related to: Ticagrelor: Positive, negative and misunderstood properties as a new antiplatelet agent

  1. You have full text access to this OnlineOpen article
    Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 10, October 2014, Pages: 1077–1090, Paul P. Dobesh and Julie H. Oestreich

    Version of Record online : 28 AUG 2014, DOI: 10.1002/phar.1477

  2. You have full text access to this OnlineOpen article
    Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist

    Cardiovascular Therapeutics

    Volume 27, Issue 4, Winter 2009, Pages: 259–274, Steen Husted and J.J.J. Van Giezen

    Version of Record online : 10 JUL 2009, DOI: 10.1111/j.1755-5922.2009.00096.x

  3. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 6, December 2012, Pages: 704–711, R. Teng and K. Butler

    Version of Record online : 2 JUL 2012, DOI: 10.1111/j.1365-2710.2012.01367.x

  4. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment

    The Journal of Clinical Pharmacology

    Volume 51, Issue 7, July 2011, Pages: 978–987, Kathleen Butler and Renli Teng

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010379409

  5. You have free access to this content
    Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease

    British Journal of Clinical Pharmacology

    Volume 82, Issue 2, August 2016, Pages: 352–361, Haiyan Li, Jingchuan Guo, Glenn F. Carlson and Renli Teng

    Version of Record online : 9 JUN 2016, DOI: 10.1111/bcp.12950

  6. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach

    Clinical Pharmacology & Therapeutics

    Volume 100, Issue 3, September 2016, Pages: 295–304, N Marsousi, CF Samer, P Fontana, JL Reny, S Rudaz, JA Desmeules and Y Daali

    Version of Record online : 25 JUL 2016, DOI: 10.1002/cpt.407

  7. You have free access to this content
    Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 70, Issue 1, July 2010, Pages: 65–77, Kathleen Butler and Renli Teng

    Version of Record online : 22 MAR 2010, DOI: 10.1111/j.1365-2125.2010.03669.x

  8. You have full text access to this OnlineOpen article
    Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling

    CPT: Pharmacometrics & Systems Pharmacology

    Volume 5, Issue 6, June 2016, Pages: 313–323, J Almquist, M Penney, S Pehrsson, A-S Sandinge, A Janefeldt, S Maqbool, S Madalli, J Goodman, S Nylander and P Gennemark

    Version of Record online : 16 JUN 2016, DOI: 10.1002/psp4.12089

  9. You have free access to this content
    Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project)

    British Journal of Clinical Pharmacology

    Volume 77, Issue 5, May 2014, Pages: 746–755, Bernard Vrijens, Marc J. Claeys, Victor Legrand, Eef Vandendriessche and Frans Van de Werf

    Version of Record online : 22 APR 2014, DOI: 10.1111/bcp.12275

  10. You have free access to this content
    Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 75, Issue 6, June 2013, Pages: 1488–1496, Mikko T. Holmberg, Aleksi Tornio, Lotta Joutsi-Korhonen, Mikko Neuvonen, Pertti J. Neuvonen, Riitta Lassila, Mikko Niemi and Janne T. Backman

    Version of Record online : 20 MAY 2013, DOI: 10.1111/bcp.12026

  11. Evaluation and Characterization of the Effects of Ticagrelor on Serum and Urinary Uric Acid in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 2, February 2012, Pages: 264–271, K Butler and R Teng

    Version of Record online : 21 DEC 2011, DOI: 10.1038/clpt.2011.223

  12. Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary Syndrome

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 3, March 2012, Pages: 244–273, Kathleen A. Packard, Jennifer A. Campbell, Jon T. Knezevich and Estella M. Davis

    Version of Record online : 28 FEB 2012, DOI: 10.1002/j.1875-9114.2012.01021.x

  13. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 6, June 2011, Pages: 2194–2202, Kalle Sigfridsson, Jan-Arne Björkman, Pia Skantze and Helen Zachrisson

    Version of Record online : 22 DEC 2010, DOI: 10.1002/jps.22440

  14. You have free access to this content
    High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 6, June 2015, Pages: 931–942, G. Lemesle, G. Schurtz, C. Bauters and M. Hamon

    Version of Record online : 21 APR 2015, DOI: 10.1111/jth.12907

  15. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment

    The Journal of Clinical Pharmacology

    Volume 52, Issue 9, September 2012, Pages: 1388–1398, Kathleen Butler and Renli Teng

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011415526

  16. Ticagrelor mitigates ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males – a randomised, single-blinded study

    British Journal of Clinical Pharmacology

    Accepted manuscript online: 17 JUL 2017, Stefan Weisshaar, Brigitte Litschauer, Matthias Eipeldauer, Eva Luise Hobl and Michael Wolzt

    DOI: 10.1111/bcp.13378

  17. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 4, August 2012, Pages: 464–468, R. Teng, P. D. Mitchell and K. Butler

    Version of Record online : 4 OCT 2011, DOI: 10.1111/j.1365-2710.2011.01307.x

  18. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects

    Journal of Thrombosis and Haemostasis

    Volume 14, Issue 12, December 2016, Pages: 2342–2352, R. Teng, G. F. Carlson, S. Nylander and T. L. G. Andersson

    Version of Record online : 31 OCT 2016, DOI: 10.1111/jth.13511

  19. Ticagrelor-induced dyspnoea

    Journal of Pharmacy Practice and Research

    Volume 45, Issue 3, September 2015, Pages: 310–313, Beryl Lai

    Version of Record online : 28 SEP 2015, DOI: 10.1002/jppr.1119

  20. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells

    Fundamental & Clinical Pharmacology

    Volume 30, Issue 6, December 2016, Pages: 577–584, Niloufar Marsousi, Fabienne Doffey-Lazeyras, Serge Rudaz, Jules A. Desmeules and Youssef Daali

    Version of Record online : 5 AUG 2016, DOI: 10.1111/fcp.12219